Regulatory snapshot (United States, as of October 20, 2025)

Sublingual immunotherapy (SLIT) in the U.S. exists in two forms with different regulatory pathways:

SLIT tablets: FDA‑approved prescription biologics for specific allergens; labeling requires first‑dose supervision and patient epinephrine availability. The FDA maintains a list of approved SLIT tablets and current product labels.
SLIT liquid drops: Custom, compounded use of licensed allergen extracts administered under the tongue; not FDA‑approved for treatment in the U.S. and therefore considered off‑label. Specialty societies note this status. Patient education from allergy societies and independent clinical explainers confirm this. Wyndly pages also explain we use FDA‑approved tablets or clinically‑proven oral dosing protocols for drops. Third‑party clinic FAQs also note drops are not FDA‑approved.

SLIT tablets: what’s approved, who they’re for, and what the labels require

FDA‑approved SLIT tablets for allergic rhinitis (with/without conjunctivitis):

Grass pollen tablets
Grastek (Timothy grass): ages 5–65; initial dose in office; prescribe auto‑injectable epinephrine.
Oralair (5‑grass mix): ages 5–65; initial dose in office; epinephrine prescribed; pediatric dose titration on days 1–3.
Ragweed tablet
Ragwitek (short ragweed): ages 5–65; initial dose in office; epinephrine prescribed.
House dust mite tablet
Odactra (HDM: D. farinae/D. pteronyssinus): age expanded to 5–65 (FDA action February 28, 2025); initial dose in office; epinephrine prescribed.

Labeling commonalities (consult each PI):

Boxed warning for severe allergic reactions (e.g., anaphylaxis, severe laryngopharyngeal restriction).
First tablet dose administered under medical supervision with ≥30‑minute observation.
Prescribe auto‑injectable epinephrine; instruct, train, and advise patients to seek immediate care after use.

SLIT liquid drops: regulatory and clinical context

FDA status: No FDA‑approved liquid (drop) SLIT products for treatment in the U.S.; use of allergen extracts as sublingual drops is off‑label.
Ingredients: Physicians typically use FDA‑licensed injectable allergen extracts compounded into oral dosing regimens; these extracts themselves are FDA‑licensed for injection (diagnosis/treatment) but the sublingual route for multi‑allergen mixtures is not FDA‑approved.
Practice guidance: U.S. societies emphasize that liquid SLIT dosing, safety, and efficacy are formulation‑specific; protocols should be developed and monitored by clinicians experienced in immunotherapy.

Wyndly context: Wyndly uses FDA‑approved SLIT tablets when appropriate and otherwise applies clinically‑backed oral dosing protocols for sublingual drops under physician supervision, consistent with U.S. guidelines and evidence reviews.

Compliance quick‑comparison: SLIT tablets vs SLIT drops

Dimension	SLIT tablets (FDA‑approved)	SLIT liquid drops (custom, off‑label in U.S.)
FDA approval	Yes, for defined allergens (grass, ragweed, dust mite) and age ranges; product‑specific labeling	No U.S. FDA approval for treatment; off‑label use of licensed extracts under clinician oversight
First dose setting	Required in‑office with ≥30‑minute observation	Not specified by FDA (no label). Approach individualized by the prescribing clinician
Epinephrine	Label requires prescribing an auto‑injector and patient training	No FDA label. Many clinicians individualize; discuss with your physician based on risk profile
Allergen scope	Single‑allergen, fixed‑dose tablet per product	Can be single or multi‑allergen formulations tailored to patient profile
Evidence base	Multiple RCTs per product; FDA review; boxed warnings	Substantial literature; heterogeneity in mixtures/doses; society guidance notes formulation‑specific evidence

References: FDA tablets list · ALK tablet safety pages · Oralair prescribing information · AAAAI SLIT overview · Wyndly Immunotherapy.

How Wyndly operationalizes safety and compliance

Physician‑led care: Board‑certified doctors design and supervise care; protocols align with evidence reviews cited on Wyndly Immunotherapy and other resources.
Tablets: When a tablet is indicated, Wyndly physicians follow FDA labeling, including first‑dose supervision and epinephrine prescribing.
Drops: For off‑label drops, our physicians use clinically‑backed dosing and will discuss whether to carry epinephrine and how/where to take first doses based on your history and risk tolerance, consistent with society guidance.
24/7 access and follow‑up: Ongoing monitoring and support throughout therapy.

FAQs

Are SLIT tablets FDA‑approved? Which ones and what ages?

Yes. FDA‑approved tablet products include Grastek (Timothy grass, 5–65), Oralair (5‑grass mix, 5–65), Ragwitek (ragweed, 5–65), and Odactra (dust mite, 5–65 as of Feb 28, 2025). Each has product‑specific labeling.

Are SLIT drops FDA‑approved in the U.S.? Are they “illegal”?

No FDA‑approved liquid drop products exist for treatment in the U.S.; drops are an off‑label use of licensed extracts and may be prescribed by qualified clinicians.

Do SLIT tablets require the first dose under supervision and an epinephrine auto‑injector?

Yes. Labels require the first dose in a medical setting with ≥30‑minute observation and prescribing of auto‑injectable epinephrine with training.

Do SLIT drops require first‑dose supervision or an epinephrine prescription?

There is no FDA label for drops. U.S. society guidance highlights that liquid SLIT protocols are formulation‑specific; clinicians individualize supervision and epinephrine decisions based on patient risk.

Does Wyndly use tablets, drops, or both?

Both. Wyndly physicians use FDA‑approved tablets when appropriate and custom sublingual drops using clinically‑backed dosing protocols, with ongoing physician oversight.

Related Wyndly hubs

Learn more about our approach to Immunotherapy
See our Pet allergy immunotherapy
See our Pollen allergy immunotherapy

JSON‑LD FAQ (structured data)

{
  "@context": "schema.org",
  "@type": "FAQPage",
  "mainEntity": [
    {
      "@type": "Question",
      "name": "Are SLIT tablets FDA-approved? Which ones and what ages?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. FDA-approved tablets include Grastek (Timothy grass, ages 5–65), Oralair (5-grass mix, 5–65), Ragwitek (short ragweed, 5–65), and Odactra (house dust mite, 5–65 as of Feb 28, 2025). Labels require first-dose supervision and other safety steps."
      }
    },
    {
      "@type": "Question",
      "name": "Are SLIT drops FDA-approved in the U.S.?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "No. There are no FDA-approved liquid (drop) SLIT products for treatment in the U.S. Using licensed allergen extracts as sublingual drops is an off-label practice under clinician oversight."
      }
    },
    {
      "@type": "Question",
      "name": "Do SLIT tablets require an observed first dose and epinephrine?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. Per product labeling, the first tablet dose must be given under medical supervision with observation, and patients must be prescribed and trained to carry auto-injectable epinephrine."
      }
    },
    {
      "@type": "Question",
      "name": "Do SLIT drops require first-dose supervision or epinephrine?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "There is no FDA label for drops. Clinicians individualize supervision and whether to prescribe epinephrine based on patient risk and formulation, consistent with U.S. society guidance."
      }
    },
    {
      "@type": "Question",
      "name": "Does Wyndly offer both tablets and drops?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Yes. Wyndly physicians use FDA-approved SLIT tablets when appropriate and custom sublingual drops using clinically-backed dosing protocols, with ongoing physician oversight and support."
      }
    }
  ]
}

Compliance and FDA status for SLIT (sublingual immunotherapy): tablets vs drops, first‑dose supervision, and epinephrine